https://www.pharmalawgrp.com/ 2026-03-31 weekly 1.0 https://www.pharmalawgrp.com/blog/ 2026-01-15 weekly 0.6 https://www.pharmalawgrp.com/regulatory-ip/ 2024-09-24 monthly 0.6 https://www.pharmalawgrp.com/news/ 2025-05-13 monthly 0.6 https://www.pharmalawgrp.com/video/ 2021-04-25 weekly 0.6 https://www.pharmalawgrp.com/page/biography/ 2025-09-02 monthly 0.5 https://www.pharmalawgrp.com/page/biologics-biosimilars/ 2021-08-30 monthly 0.5 https://www.pharmalawgrp.com/page/bpcia/ 2021-07-26 monthly 0.5 https://www.pharmalawgrp.com/page/contact/ 2024-10-28 monthly 0.5 https://www.pharmalawgrp.com/page/education/ 2019-05-19 monthly 0.5 https://www.pharmalawgrp.com/page/expert-witness/ 2024-07-22 monthly 0.5 https://www.pharmalawgrp.com/page/hatch-waxman/ 2021-06-28 monthly 0.5 https://www.pharmalawgrp.com/page/life-sciences/ 2019-05-19 monthly 0.5 https://www.pharmalawgrp.com/page/lifecycle-management/ 2025-02-26 monthly 0.5 https://www.pharmalawgrp.com/page/patent-regulatory-exclusivity-analysis/ 2023-04-12 monthly 0.5 https://www.pharmalawgrp.com/page/personalized-medicine/ 2023-03-29 monthly 0.5 https://www.pharmalawgrp.com/page/pharma/ 2023-05-02 monthly 0.5 https://www.pharmalawgrp.com/page/practice/ 2019-05-19 monthly 0.5 https://www.pharmalawgrp.com/page/product-development/ 2021-06-28 monthly 0.5 https://www.pharmalawgrp.com/page/publications/ 2019-05-19 monthly 0.5 https://www.pharmalawgrp.com/page/regulatory-issues/ 2023-08-02 monthly 0.5 https://www.pharmalawgrp.com/page/service/ 2019-05-19 monthly 0.5 https://www.pharmalawgrp.com/page/transaction-advice/ 2023-07-07 monthly 0.5 https://www.pharmalawgrp.com/video/1/demystifying-pharma/ 2019-05-20 monthly 0.5 https://www.pharmalawgrp.com/video/2/questions-answers/ 2019-05-19 monthly 0.5 https://www.pharmalawgrp.com/blog/2/the-importance-of-umbrella-exclusivity-for-biologics/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/4/benefits-of-fda-pediatric-exclusivity/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/7/can-the-fda-require-post-market-efficacy-studies/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/1/anda-section-viii-label-carve-outs-explained/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/15/what-gsk-v-teva-means-for-anda-skinny-labels/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/18/cms-new-formulation-definition-upheld-implications-for-drug-companies/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/26/life-cycle-benefits-of-cross-referencing-clinical-studies/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/23/alphafold-3-ai-tools-in-drug-discovery/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/21/fda-proposes-dropping-switching-studies-for-biosimilar-interchangeability/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/19/competitive-effects-of-overlapping-drug-exclusivities/ 2026-01-15 never 0.5 https://www.pharmalawgrp.com/blog/28/enhancing-life-cycle-management-through-late-stage-pharmaceutical-patent-protection/ 2025-10-31 never 0.5 https://www.pharmalawgrp.com/blog/27/key-facts-on-the-commissioners-national-priority-voucher-cnpv-program/ 2025-09-22 never 0.5 https://www.pharmalawgrp.com/blog/25/what-teva-v-amneal-means-for-orange-book-listings/ 2025-03-19 never 0.5 https://www.pharmalawgrp.com/blog/24/fda-decision-on-boehringers-cyltezo-clarifies-fie-expiration/ 2025-03-06 never 0.5 https://www.pharmalawgrp.com/blog/22/recursion-exscientia-merger-ais-impact-on-modern-drug-discovery/ 2025-02-27 never 0.5 https://www.pharmalawgrp.com/blog/20/new-fda-draft-guidance-aims-to-limit-pediatric-exclusivity-extension-awards/ 2024-06-13 never 0.5 https://www.pharmalawgrp.com/blog/17/fda-proposes-treating-pandas-like-full-ndas/ 2023-05-11 never 0.5 https://www.pharmalawgrp.com/blog/16/rx-to-otc-switch-are-the-same-listing-no-180-day-exclusivity/ 2023-04-25 never 0.5 https://www.pharmalawgrp.com/blog/14/court-says-fda-unlawfully-infringed-on-catalyst-orphan-drug-exclusivity-with-ruzurgi-approval/ 2023-03-07 never 0.5 https://www.pharmalawgrp.com/blog/13/the-enduring-role-of-orphan-drug-exclusivity-for-biologics/ 2021-10-19 never 0.5 https://www.pharmalawgrp.com/blog/3/fda-extends-its-rare-pediatric-disease-prv-program/ 2021-04-05 never 0.5 https://www.pharmalawgrp.com/blog/11/fda-issues-final-guidance-on-lpad-pathway/ 2020-12-18 never 0.5 https://www.pharmalawgrp.com/blog/9/new-fda-guidance-details-how-to-submit-pediatric-study-plans/ 2020-12-10 never 0.5 https://www.pharmalawgrp.com/blog/10/fda-changes-definition-of-biological-product/ 2020-12-10 never 0.5 https://www.pharmalawgrp.com/blog/8/new-opportunity-for-otc-product-market-exclusivity/ 2020-09-08 never 0.5 https://www.pharmalawgrp.com/blog/6/fusion-protein-orphan-drug-designation-required-clinical-superiority-hypothesis/ 2019-08-19 never 0.5 https://www.pharmalawgrp.com/blog/5/how-drug-companies-get-multiple-exclusivity-periods-for-1-orphan-indication/ 2019-08-19 never 0.5